Kallyope posts modest obesity data as competition heats up

Kallyope’s latest obesity drug trial results show modest weight-loss effects that lag behind competing therapies in the increasingly competitive obesity treatment market.

The company’s Phase II study, which tested its oral nutrient receptor agonists, found that while the drug combination achieved statistical significance, the overall weight reduction was relatively small compared to market leaders.

Participants received either Kallyope’s experimental drug K-757 as a standalone treatment, a combination of K-757 and K-833, or a placebo. The results, posted to a clinical trial database without fanfare, show K-757 alone provided a 1.57% reduction in body weight after 13 weeks.